Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: Another autograft or switch to allograft?

C. O. Freytes, H. M. Lazarus

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.

Original languageEnglish (US)
Pages (from-to)559-569
Number of pages11
JournalBone Marrow Transplantation
Volume44
Issue number9
DOIs
StatePublished - 2009

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: Another autograft or switch to allograft?'. Together they form a unique fingerprint.

Cite this